The Alterations of Metabolic Adipo-myokines and Body Composition in End Stage Lung Cancer
Launched by CHANG GUNG MEMORIAL HOSPITAL · Sep 24, 2023
Trial Information
Current as of May 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how changes in body composition and certain substances in the blood, known as adipo-myokines, relate to the effects of chemotherapy and the overall prognosis (outlook) for patients with advanced lung cancer. The researchers want to understand how these factors might affect patients' health and treatment outcomes as they undergo chemotherapy.
To participate in this trial, individuals need to be adults over 20 years old who have been diagnosed with stage III to stage IV lung cancer and have a daily performance status that allows them to engage in normal activities (rated between 0 and 2 on a scale). Unfortunately, people with cardiac stents or pacemakers are not eligible for this study. Participants can expect to be closely monitored throughout the trial, which will help researchers gather important information that may improve future treatments for lung cancer. The study is currently looking for volunteers to join.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Diagnosis of lung cancer stage III to stage IV
- • 2. Adults over 20 years old
- • 3. Daily performance status of 0- 2
- Exclusion Criteria:
- • 1. Cardiac stents or pacemakers
About Chang Gung Memorial Hospital
Chang Gung Memorial Hospital, one of the largest healthcare organizations in Taiwan, is renowned for its commitment to advancing medical research and improving patient care. As a clinical trial sponsor, the hospital leverages its extensive clinical expertise and state-of-the-art facilities to conduct innovative research across various medical disciplines. With a focus on collaboration and ethical practices, Chang Gung Memorial Hospital aims to contribute to the global body of medical knowledge through rigorous clinical trials that enhance treatment options and improve health outcomes for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kaohsiung City, , Taiwan
Patients applied
Trial Officials
TSENG CHIA-CHENG
Principal Investigator
Chang Gung Memorial Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported